Primrose Bio

Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation Therapeutics

June 17 2024 - California, US – Primrose Bio, Inc. (“Primrose,” the “company”), a company focused on developing and licensing its manufacturing technologies for nucleic acids and proteins used in therapeutics and vaccines, announced a significant equity investment from 1315 Capital, a Philadelphia-based, healthcare-focused growth equity firm. These funds will enable the continued development and...
Primrose Bio, 10790 Roselle Street, San Diego, CA 92121 United States